GlobeNewswire Inc.··NaBiodexa Pharmaceuticals Executes 1-for-5 Reverse ADR Split to Maintain Nasdaq Listing
Biodexa Pharmaceuticals executes 1-for-5 reverse ADR split effective April 6, 2026, to maintain Nasdaq listing compliance with minimum bid price requirements.
BDRXbiopharmaceuticalrare diseases